Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome
Conditions
Interventions
Miransertib
Locations
11
United States
Children's Hospital of Atlanta ( Site 0107)
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0101)
Chicago, Illinois, United States
Boston Children's Hospital ( Site 0089)
Boston, Massachusetts, United States
Cincinnati Children's Hospital Medical Center ( Site 0102)
Cincinnati, Ohio, United States
Texas Children's Hospital ( Site 0104)
Houston, Texas, United States
Seattle Childrens Hospital ( Site 0103)
Seattle, Washington, United States
Start Date
May 16, 2017
Primary Completion Date
April 11, 2022
Completion Date
April 11, 2022
Last Updated
April 13, 2023
Lead Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions